Browse by Series:

Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

FACP, University of Pittsburgh School of Medicine; Hope S. Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center; Lee Schwartzberg, MD, FACP, West Cancer Center SAMPLE Panelists:KOL NAME, institution; Breast Cancer Broadcast/News
Published: Thursday, Feb 01, 2018



With the advent of recent data, there is a focus on incorporating them into the treatment planning of HER2-positive early breast cancer. Adam M. Brufsky, MD, PhD, FACP, leads panel of experts, Kimberly Blackwell, MD; Hope S. Rugo, MD; and Lee Schwartzberg, MD, FACP, on addressing some of the questions surrounding adjuvant treatment of HER2-positive early breast cancer and how they interpret the available data.
 
Slider Left
Slider Right


With the advent of recent data, there is a focus on incorporating them into the treatment planning of HER2-positive early breast cancer. Adam M. Brufsky, MD, PhD, FACP, leads panel of experts, Kimberly Blackwell, MD; Hope S. Rugo, MD; and Lee Schwartzberg, MD, FACP, on addressing some of the questions surrounding adjuvant treatment of HER2-positive early breast cancer and how they interpret the available data.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x